Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity.

Cazaux M, Grandjean CL, Lemaître F, Garcia Z, Beck RJ, Milo I, Postat J, Beltman JB, Cheadle EJ, Bousso P.

J Exp Med. 2019 May 6;216(5):1038-1049. doi: 10.1084/jem.20182375. Epub 2019 Apr 1.

PMID:
30936262
2.

Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.

Owens GL, Price MJ, Cheadle EJ, Hawkins RE, Gilham DE, Edmondson RJ.

Cancer Immunol Immunother. 2018 Oct;67(10):1519-1531. doi: 10.1007/s00262-018-2211-3. Epub 2018 Jul 23.

3.

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.

Owens GL, Sheard VE, Kalaitsidou M, Blount D, Lad Y, Cheadle EJ, Edmondson RJ, Kooner G, Gilham DE, Harrop R.

J Immunother. 2018 Apr;41(3):130-140. doi: 10.1097/CJI.0000000000000203.

4.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Oct;31(10):2278. doi: 10.1038/leu.2017.218. Epub 2017 Jul 28.

PMID:
28751765
5.

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.

Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, Robins HS, Wilkinson RW, Honeychurch J, Illidge TM.

Clin Cancer Res. 2017 Sep 15;23(18):5514-5526. doi: 10.1158/1078-0432.CCR-16-1673. Epub 2017 May 22.

6.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Jul;31(7):1611-1621. doi: 10.1038/leu.2016.352. Epub 2017 Nov 28. Erratum in: Leukemia. 2017 Jul 28;:.

7.

Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L, Glennie MJ, Illidge TM, Honeychurch J.

Cancer Immunol Res. 2016 Jul;4(7):621-630. doi: 10.1158/2326-6066.CIR-15-0253. Epub 2016 May 30.

8.

Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.

Lipowska-Bhalla G, Fagnano E, Illidge TM, Cheadle EJ.

Leuk Lymphoma. 2016;57(6):1269-80. doi: 10.3109/10428194.2016.1157874. Epub 2016 Apr 6. Review.

PMID:
27050042
9.

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.

Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM.

Oncotarget. 2016 Mar 29;7(13):17035-46. doi: 10.18632/oncotarget.7928.

10.

Immuno-regulatory antibodies for the treatment of cancer.

Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM.

Expert Opin Biol Ther. 2015 Jun;15(6):787-801. doi: 10.1517/14712598.2015.1036737. Epub 2015 Apr 16. Review.

PMID:
25882106
11.

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM.

Cancer Res. 2014 Oct 1;74(19):5458-68. doi: 10.1158/0008-5472.CAN-14-1258.

12.

Update on obinutuzumab in the treatment of B-cell malignancies.

Illidge T, Cheadle EJ, Donaghy C, Honeychurch J.

Expert Opin Biol Ther. 2014 Oct;14(10):1507-17. doi: 10.1517/14712598.2014.948414. Epub 2014 Sep 5. Review.

PMID:
25190612
13.

Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.

Cheadle EJ, Sheard V, Rothwell DG, Bridgeman JS, Ashton G, Hanson V, Mansoor AW, Hawkins RE, Gilham DE.

J Immunol. 2014 Apr 15;192(8):3654-65. doi: 10.4049/jimmunol.1302148. Epub 2014 Mar 12.

14.

CAR T cells: driving the road from the laboratory to the clinic.

Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE.

Immunol Rev. 2014 Jan;257(1):91-106. doi: 10.1111/imr.12126. Review.

PMID:
24329792
15.

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.

Guest RD, Kirillova N, Mowbray S, Gornall H, Rothwell DG, Cheadle EJ, Austin E, Smith K, Watt SM, Kühlcke K, Westwood N, Thistlethwaite F, Hawkins RE, Gilham DE.

Cancer Immunol Immunother. 2014 Feb;63(2):133-45. doi: 10.1007/s00262-013-1492-9. Epub 2013 Nov 5.

PMID:
24190544
16.

New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor.

Illidge TM, Cheadle EJ, Honeychurch J.

Leuk Lymphoma. 2014 Jan;55(1):3-4. doi: 10.3109/10428194.2013.797976. Epub 2013 Oct 24. No abstract available.

PMID:
24047477
17.

Targeting T cells to tumor: exploiting the chimeric antibody receptor.

Gilham DE, Cheadle EJ.

Immunotherapy. 2013 Sep;5(9):927-9. doi: 10.2217/imt.13.92.

PMID:
23998728
18.

The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.

Cheadle EJ, Sidon L, Dovedi SJ, Melis MH, Alduaij W, Illidge TM, Honeychurch J.

Br J Haematol. 2013 Sep;162(6):842-5. doi: 10.1111/bjh.12427. Epub 2013 Jun 18. No abstract available.

PMID:
23772929
19.

Chimeric antigen receptors for T-cell based therapy.

Cheadle EJ, Sheard V, Hombach AA, Chmielewski M, Riet T, Berrevoets C, Schooten E, Lamers C, Abken H, Debets R, Gilham DE.

Methods Mol Biol. 2012;907:645-66. doi: 10.1007/978-1-61779-974-7_36.

PMID:
22907378
20.

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.

Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, Huang P, Cragg MS, Illidge TM.

Blood. 2012 Apr 12;119(15):3523-33. doi: 10.1182/blood-2011-12-395541. Epub 2012 Feb 21.

21.

Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells.

Cheadle EJ, Rothwell DG, Bridgeman JS, Sheard VE, Hawkins RE, Gilham DE.

Gene Ther. 2012 Nov;19(11):1114-20. doi: 10.1038/gt.2011.192. Epub 2011 Dec 1.

PMID:
22130449
22.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM.

Blood. 2011 Apr 28;117(17):4519-29. doi: 10.1182/blood-2010-07-296913. Epub 2011 Mar 4.

23.

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE.

J Immunol. 2010 Feb 15;184(4):1885-96. doi: 10.4049/jimmunol.0901440. Epub 2010 Jan 20.

24.

The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, Italy.

Bridgeman JS, Gilham DE, Hawkins RE, Cheadle EJ.

Cancer Immunol Immunother. 2010 Jun;59(6):971-4. doi: 10.1007/s00262-009-0748-x. Epub 2009 Aug 8. No abstract available.

PMID:
19669146
25.

Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.

Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE.

J Immunother. 2009 Apr;32(3):207-18. doi: 10.1097/CJI.0b013e318194a921.

PMID:
19242379
26.

The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.

Cheadle EJ, Gilham DE, Hawkins RE.

Br J Haematol. 2008 Jul;142(1):65-8. doi: 10.1111/j.1365-2141.2008.07145.x. Epub 2008 May 8.

PMID:
18477047
27.

Eotaxin-2 and colorectal cancer: a potential target for immune therapy.

Cheadle EJ, Riyad K, Subar D, Rothwell DG, Ashton G, Batha H, Sherlock DJ, Hawkins RE, Gilham DE.

Clin Cancer Res. 2007 Oct 1;13(19):5719-28.

28.

MT-103 Micromet/MedImmune.

Cheadle EJ.

Curr Opin Mol Ther. 2006 Feb;8(1):62-8.

PMID:
16506527
29.

Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin.

Armstrong AC, Cheadle EJ, Hawkins RE.

BioDrugs. 2005;19(5):289-97. Review.

PMID:
16207070
30.

Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.

Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE.

Br J Haematol. 2005 May;129(3):322-32.

PMID:
15842655
31.

The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.

Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, Embleton MJ, Stern PL, Gilham DE.

J Immunother. 2005 May-Jun;28(3):203-11.

PMID:
15838376
34.

A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy.

Radford KJ, Higgins DE, Pasquini S, Cheadle EJ, Carta L, Jackson AM, Lemoine NR, Vassaux G.

Gene Ther. 2002 Nov;9(21):1455-63.

35.

Bugs as drugs for cancer.

Cheadle EJ, Jackson AM.

Immunology. 2002 Sep;107(1):10-9. Review. No abstract available.

Supplemental Content

Loading ...
Support Center